SCHEMBL2701430

SCHEMBL2701430

NC(=O)c1nc2cc(Cl)ccc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
LMNA P02545 2/20 0.57
CYP1A2 P05177 1/20 0.57
THRB P10828 1/20 0.57
ALOX15 P16050 1/20 0.57
MAPK1 P28482 1/20 0.57
XDH P47989 1/20 0.50
KDM4E B2RXH2 5/20 0.49
PSMB8 P28062 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
KCNH2 Q12809 2/20 0.48
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
CASP3 P42574 3/20 0.47
SENP7 Q9BQF6 3/20 0.47
SENP6 Q9GZR1 1/20 0.47
POLB P06746 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27654631 0.88 MAPT (0.58) MAPTLMNACYP1A2THRBALOX15
SCHEMBL29825622 0.85 MEN1 (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL3640007 0.85 MEN1 (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL11233556 0.85 MAPT (0.54) MAPTLMNACYP1A2THRBALOX15
SCHEMBL10829146 0.82 XDH (0.52) MAPTLMNACYP1A2THRBALOX15
SCHEMBL5095572 0.80 MEN1 (0.51) MAPTLMNACYP1A2THRBALOX15
SCHEMBL10829024 0.80 MAPT (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL7535843 0.79 NPC1 (0.44) MAPTTHRBXDHKDM4EMEN1
SCHEMBL14047971 0.76 FFAR2 (0.60) MAPTLMNACYP1A2THRBALOX15
SCHEMBL11309125 0.76 KMT2A (0.55) MAPTLMNACYP1A2THRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904439-B1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTHECHNOLOGY CORP (US) 2014-11-26 EP claimed
US-8557800-B2 Sphingosine kinase inhibitors APOGEE BIOTECHNOLOGY CORPORATION (US) 2013-10-15 US claimed
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP claimed
US-20100234377-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE EVOTEC AG (DE) 2010-09-16 US claimed
US-20100137315-A1 Sphingosine Kinase Inhibitors and Methods of Their Use APOGEE BIOTECHNOLOGY CORPORATION (US) 2010-06-03 US claimed
EP-2150532-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE Evotec AG (DE) 2010-02-10 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
WO-2008122787-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE EVOTEC AG (DE) 2008-10-16 WO claimed
EP-1928848-A2 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE Apogee Biothechnology Corporation (US) 2008-06-11 EP claimed
EP-1904439-A2 SPHINGOSINE KINASE INHIBITORS Apogee Biothechnology Corporation (US) 2008-04-02 EP claimed
WO-2007019251-A9 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORP (US) 2007-04-19 WO claimed
WO-2007019251-A2 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-15 WO claimed
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-08 US claimed
WO-2006138660-A2 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-28 WO claimed
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-21 US claimed
EP-1034176-A1 THIOPHENE-SULFONAMIDE COMPOUNDS PHARMACIA & UPJOHN S.p.A. (IT) 2000-09-13 EP claimed
WO-1999028316-A1 THIOPHENE-SULFONAMIDE COMPOUNDS PHARMACIA & UPJOHN S.P.A. (IT) 1999-06-10 WO claimed
US-RE49811-E1 Sphingosine kinase inhibitors APOGEE BIOTECHNOLOGY CORPORATION (US) 2024-01-23 US disclosed
EP-1034176-A1 THIOPHENE-SULFONAMIDE COMPOUNDS PHARMACIA & UPJOHN S.p.A. (IT) 2000-09-13 EP disclosed
WO-1999028316-A1 THIOPHENE-SULFONAMIDE COMPOUNDS PHARMACIA & UPJOHN S.P.A. (IT) 1999-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS SPHK1, SPHK2, S1PR1 MAPT 1695/4885LMNA 1777/4885CYP1A2 3594/4885
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE SPHK1, SPHK2, S1PR2 MAPT 2371/4885LMNA 1345/4885CYP1A2 4393/4885
US-20100234377-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE HPGDS, PTGDR, PTGIS MAPT 4774/4885LMNA 1934/4885CYP1A2 652/4885
US-20100137315-A1 Sphingosine Kinase Inhibitors and Methods of Their Use SPHK1, SPHK2, S1PR2 MAPT 2338/4885LMNA 1466/4885CYP1A2 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.